Department of Surgery, Division of Surgical Oncology, University of Miami Miller School of Medicine, Miami, Florida.
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
JAMA Netw Open. 2024 Apr 1;7(4):e247336. doi: 10.1001/jamanetworkopen.2024.7336.
Despite improvements in breast cancer screening, treatment, and survival, disparate breast cancer-specific survival outcomes persist, particularly in disadvantaged neighborhoods. Most of these disparities are attributed to disparities in individual, tumor, and treatment characteristics. However, a critical knowledge gap exists as to whether disparities in breast cancer-specific survival remain after accounting for individual, tumor, and treatment characteristics.
To evaluate if neighborhood disadvantage is associated with shorter breast cancer-specific survival after controlling for individual, tumor, and treatment characteristics in a national population.
DESIGN, SETTING, AND PARTICIPANTS: This national retrospective cohort study included patients with breast cancer diagnosed from 2013 to 2018 from the Surveillance, Epidemiology, and End Results 17 Census tract-level socioeconomic status and rurality database of the National Cancer Institute. Data analysis was performed from September 2022 to December 2023.
Neighborhood disadvantage measured by Yost index quintiles.
Breast cancer-specific survival was evaluated using a competing risks cause-specific hazard model controlling for age, race, ethnicity, rurality, stage, subtype, insurance, and receipt of treatment.
A total of 350 824 patients with breast cancer were included; 41 519 (11.8%) were Hispanic, 39 631 (11.3%) were non-Hispanic Black, and 234 698 (66.9%) were non-Hispanic White. A total of 87 635 patients (25.0%) lived in the most advantaged neighborhoods (group 5) and 52 439 (14.9%) lived in the most disadvantaged neighborhoods (group 1). A larger number of non-Hispanic White patients (66 529 patients [76.2%]) lived in advantaged neighborhoods, while disadvantaged neighborhoods had the highest proportion of non-Hispanic Black (16 141 patients [30.9%]) and Hispanic patients (10 168 patients [19.5%]). Breast cancer-specific survival analysis found the most disadvantaged neighborhoods (group 1) had the highest risk of mortality (hazard ratio, 1.43; 95% CI, 1.36-1.50; P < .001) compared with the most advantaged neighborhoods.
In this national cohort study of patients with breast cancer, neighborhood disadvantage was independently associated with shorter breast cancer-specific survival even after controlling for individual-level factors, tumor characteristics, and treatment. This suggests potential unaccounted-for mechanisms, including both nonbiologic factors and biologic factors.
尽管乳腺癌筛查、治疗和生存方面有所改善,但仍存在明显的乳腺癌特异性生存结果差异,尤其是在处境不利的社区。这些差异大多归因于个体、肿瘤和治疗特征的差异。然而,一个关键的知识空白是,在考虑个体、肿瘤和治疗特征后,乳腺癌特异性生存是否仍然存在差异。
评估在全国人群中,个体、肿瘤和治疗特征控制后,社区劣势是否与乳腺癌特异性生存缩短相关。
设计、地点和参与者:本研究为全国回顾性队列研究,纳入了 2013 年至 2018 年期间国家癌症研究所监测、流行病学和最终结果 17 普查区层面社会经济地位和农村数据库中诊断为乳腺癌的患者。数据分析于 2023 年 9 月至 12 月进行。
社区劣势通过 Yost 指数五分位数来衡量。
使用竞争风险因果风险模型评估乳腺癌特异性生存,该模型控制年龄、种族、族裔、农村状况、分期、亚型、保险和治疗情况。
共纳入 350824 例乳腺癌患者;其中 41519 例(11.8%)为西班牙裔,39631 例(11.3%)为非西班牙裔黑人,234698 例(66.9%)为非西班牙裔白人。共有 87635 例患者(25.0%)居住在最有利的社区(第 5 组),52439 例(14.9%)居住在最不利的社区(第 1 组)。更多的非西班牙裔白人患者(66529 例[76.2%])居住在有利的社区,而不利的社区中非西班牙裔黑人(16141 例[30.9%])和西班牙裔患者(10168 例[19.5%])的比例最高。乳腺癌特异性生存分析发现,最不利的社区(第 1 组)的死亡率风险最高(风险比,1.43;95%CI,1.36-1.50;P<0.001),与最有利的社区相比。
在这项针对乳腺癌患者的全国队列研究中,即使考虑到个体水平因素、肿瘤特征和治疗情况,社区劣势仍与乳腺癌特异性生存缩短独立相关。这表明存在潜在的未被解释的机制,包括非生物学因素和生物学因素。